Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (351-360 of 713) with videos related to

Pageof 72
Sort By:
Cancer|May 14, 2008
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignanciesGautam Borthakur, Yesid Alvarado, Farhad Ravandi-Kashani, et al.
Blood|October 17, 2012
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemiaAlfonso Quintás-Cardama, Farhad Ravandi, Theresa Liu-Dumlao, et al.
Cancer|January 26, 2006
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeHagop Kantarjian, Susan O'brien, Jorge Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 4, 2009
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndromeGloria N Mattiuzzi, Jorge Cortes, Gladys Alvarado, et al.
Cancer|January 9, 2003
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndromeGloria N Mattiuzzi, Elihu Estey, Issam Raad, et al.
Cancer|December 19, 2007
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?Hagop Kantarjian, Susan O'Brien, Jianqin Shan, et al.
Cancer|October 23, 2014
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemiaJean-Pierre Issa, Guillermo Garcia-Manero, Xuelin Huang, et al.
Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.
Frontiers in Oncology|July 21, 2025
A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative reviewRola Ghasoub, Basant Elsayed, Maria Benkhadra, et al.
Pageof 72

Showing results (351-360 of 713) with videos related to

Sort By:
Pageof 72
Cancer|May 14, 2008
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignanciesGautam Borthakur, Yesid Alvarado, Farhad Ravandi-Kashani, et al.
Blood|October 17, 2012
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemiaAlfonso Quintás-Cardama, Farhad Ravandi, Theresa Liu-Dumlao, et al.
Cancer|January 26, 2006
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeHagop Kantarjian, Susan O'brien, Jorge Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 4, 2009
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndromeGloria N Mattiuzzi, Jorge Cortes, Gladys Alvarado, et al.
Cancer|January 9, 2003
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndromeGloria N Mattiuzzi, Elihu Estey, Issam Raad, et al.
Cancer|December 19, 2007
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?Hagop Kantarjian, Susan O'Brien, Jianqin Shan, et al.
Cancer|October 23, 2014
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemiaJean-Pierre Issa, Guillermo Garcia-Manero, Xuelin Huang, et al.
Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.
Frontiers in Oncology|July 21, 2025
A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative reviewRola Ghasoub, Basant Elsayed, Maria Benkhadra, et al.
Pageof 72